Search results
Results from the WOW.Com Content Network
Specifically, to count as a legitimate view, a user must intentionally initiate the playback of the video and play at least 30 seconds of the video (or the entire video for shorter videos). Additionally, while replays count as views, there is a limit of 4 or 5 views per IP address during a 24-hour period, after which point, no further views ...
For the first time ever, the FDA approved a video game as part of a treatment for children diagnosed with ADHD. The game, called EndeavorRx, is for kids aged eight through 12 to improve attention ...
EndeavorRx is a video game used to treat Attention Deficit Hyperactivity Disorder developed by Akili Interactive. It was based on a prototype game called NeuroRacer. NeuroRacer was developed by Akili Interactive and researchers at the University of San Francisco. [1] The game runs on an engine known as the Akili Selective Stimulus Management ...
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
The development of the Dornier lithotripter progressed through several prototypes, ultimately culminating in February 1980 with the first treatment of a human by shockwave lithotripsy (SWL). The production and distribution of the Dornier HM3 lithotripter began in late 1983, and SWL was approved by the U.S. Food and Drug Administration in 1984. [27]
The gene therapy will compete with Australia-based CSL Behring’s Hemgenix, a similar treatment that won FDA approval for hemophilia B in 2022. That drug has a similar list price of $3.5 million ...
Alipogene tiparvovec (Glybera): AAV-based treatment for lipoprotein lipase deficiency (no longer commercially available); Axicabtagene ciloleucel (Yescarta): treatment for large B-cell lymphoma [1]
The company also said that the FDA did not plan to hold a meeting of its outside experts to discuss the new application. The therapy, Elevidys, was granted accelerated approval in June last year ...